Long-term clinical course and treatment outcomes of individuals with Nodding Syndrome.

Epilepsy in Africa Mahenge Nodding Syndrome

Journal

Journal of the neurological sciences
ISSN: 1878-5883
Titre abrégé: J Neurol Sci
Pays: Netherlands
ID NLM: 0375403

Informations de publication

Date de publication:
14 Jan 2024
Historique:
received: 03 03 2023
revised: 28 12 2023
accepted: 13 01 2024
medline: 27 1 2024
pubmed: 27 1 2024
entrez: 26 1 2024
Statut: aheadofprint

Résumé

Nodding Syndrome is a poorly understood epilepsy disorder in sub-Saharan Africa. The cause(s) of the disease, risk factors and long-term outcomes are unknown or controversial. The objectives of this study were to describe the long-term clinical course and treatment outcomes of individuals suffering from Nodding Syndrome. In addition, we aimed to provide a comprehensive characterization of the epileptological and social features of patients with Nodding Syndrome. From 11/2014 to 4/2015, we conducted a hospital-based, cross-sectional and observational study in Mahenge, Tanzania. Seventy-eight individuals (female:male ratio: 40:38, age at examination: 21.1 ± 6.39 (SD) years) have been enrolled, of whom 38 (49%) had also been examined in 2005 and in 2009. The 10-year clinical course analysis of this revisited subgroup revealed a calculated case fatality of 0.8-2.3%. Progressive physical or cognitive deterioration has not been observed in any of the 78 individuals and more than half of the people studied (38/69; 55%) managed to live and work independently. 14/78 individuals (18%) were seizure-free, (no head nodding, no other seizure types), 13 of whom were taking antiseizure medication. Phenytoin was more effective against head nodding seizures (14/19 (74%)) than monotherapy with other available antiseizure medication (phenobarbitone 12/25 (48%) and carbamazepine 7/22 (32%), p = 0.02, chi-square test). Our ten-year clinical outcome data show that Nodding Syndrome is not a fatal disease, however, the response to treatment is worse than in epilepsy patients in general. Phenytoin may be more effective than carbamazepine and phenobarbitone, but further studies are needed to confirm this observation.

Identifiants

pubmed: 38278097
pii: S0022-510X(24)00028-5
doi: 10.1016/j.jns.2024.122893
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

122893

Informations de copyright

Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors have no competing interests to declare that are relevant to the content of this article.

Auteurs

Josua Kegele (J)

Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Hoppe-Seyler Straße 3, 72076 Tuebingen, Germany. Electronic address: josua.kegele@med.uni-tuebingen.de.

Thomas Wagner (T)

Centre for Pediatric and Adolescent Medicine, University Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany.

Teresa Kowenski (T)

Medical University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria.

Matthias Wiesmayr (M)

Medical University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria.

Christian Gatterer (C)

Medical University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria.

Michael Alber (M)

Pediatric Neurology and Developmental Medicine, University of Tübingen, Hoppe-Seyler Straße 3, 72076 Tuebingen, Germany. Electronic address: michael.alber@med.uni-tuebingen.de.

Wiliam Matuja (W)

Department of Neurology, Muhimbili University of Health and Allied Sciences, United Nations Rd, Dar es Salaam, Tanzania.

Erich Schmutzhard (E)

Department of Neurology, Medical University of Innsbruck, Innrain 52, 6020 Innsbruck, Austria. Electronic address: erich.schmutzhard@i-med.ac.at.

Holger Lerche (H)

Department of Neurology and Epileptology, Hertie Institute of Clinical Brain Research, University of Tübingen, Hoppe-Seyler Straße 3, 72076 Tuebingen, Germany. Electronic address: holger.lerche@uni-tuebingen.de.

Andrea S Winkler (AS)

Department of Neurology, Center for Global Health, School of Medicine, Technical University of Munich, Ismaninger Straße 22, 81675 Munich, Germany; Department of Community Medicine and Global Health, Institute of Health and Society, University of Oslo, Forskningsveien 3A, 0373 Oslo, Norway; Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: andrea.winkler@tum.de.

Classifications MeSH